MYND Life Sciences Announces the Issuance of 4,000,001 Shares at $0.71/share
MYND Life Sciences (MYNDF) has announced the Board's approval to issue 4,000,001 common shares at $0.71 per share, settling a previously announced $3.5 Million (CDN) debenture from January 10, 2025. The total value of the share issuance amounts to $2,840,000.71.
The company, focused on developing drug therapies and diagnostics for depression treatment and monitoring, considers this a significant milestone. According to CFO Lih Tam, this development enables MYND to engage with the investment community while advancing their mission to address major depressive disorder. The debenture settlement details will be reflected in upcoming financial statements.
MYND Life Sciences (MYNDF) ha annunciato l'approvazione da parte del Consiglio per emettere 4.000.001 azioni ordinarie a $0,71 per azione, liquidando un'obbligazione precedentemente annunciata da $3,5 milioni (CDN) del 10 gennaio 2025. Il valore totale dell'emissione di azioni ammonta a $2.840.000,71.
L'azienda, focalizzata nello sviluppo di terapie farmacologiche e diagnostiche per il trattamento e il monitoraggio della depressione, considera questo un traguardo significativo. Secondo il CFO Lih Tam, questo sviluppo consente a MYND di interagire con la comunità degli investitori mentre avanza nella loro missione di affrontare i disturbi depressivi maggiori. I dettagli della liquidazione dell'obbligazione saranno riflessi nei prossimi bilanci finanziari.
MYND Life Sciences (MYNDF) ha anunciado la aprobación de la Junta para emitir 4,000,001 acciones ordinarias a $0.71 por acción, liquidando un préstamo previamente anunciado de $3.5 millones (CDN) del 10 de enero de 2025. El valor total de la emisión de acciones asciende a $2,840,000.71.
La empresa, centrada en el desarrollo de terapias farmacológicas y diagnósticos para el tratamiento y monitoreo de la depresión, considera este un hito significativo. Según el CFO Lih Tam, este desarrollo permite a MYND interactuar con la comunidad inversora mientras avanza en su misión de abordar el trastorno depresivo mayor. Los detalles de la liquidación del préstamo se reflejarán en los próximos estados financieros.
MYND Life Sciences (MYNDF)는 4,000,001주 일반주식을 주당 $0.71에 발행하는 이사회 승인을 발표하며, 2025년 1월 10일에 발표된 $3.5백만(CDN) 채권을 상환합니다. 주식 발행의 총 가치는 $2,840,000.71입니다.
우울증 치료 및 모니터링을 위한 약물 치료 및 진단 개발에 중점을 두고 있는 이 회사는 이를 중요한 이정표로 간주합니다. CFO Lih Tam에 따르면, 이번 개발은 MYND가 투자 커뮤니티와 소통할 수 있게 하여 주요 우울 장애 문제 해결을 위한 그들의 사명을 진전시킬 수 있게 합니다. 채권 상환 세부사항은 향후 재무제표에 반영될 것입니다.
MYND Life Sciences (MYNDF) a annoncé l'approbation du Conseil pour émettre 4 000 001 actions ordinaires à 0,71 $ par action, réglant une debenture précédemment annoncée de 3,5 millions de dollars (CDN) du 10 janvier 2025. La valeur totale de l'émission d'actions s'élève à 2 840 000,71 $.
L'entreprise, qui se concentre sur le développement de thérapies médicamenteuses et de diagnostics pour le traitement et le suivi de la dépression, considère cela comme une étape significative. Selon le CFO Lih Tam, ce développement permet à MYND d'interagir avec la communauté des investisseurs tout en faisant progresser leur mission de traiter le trouble dépressif majeur. Les détails du règlement de la debenture seront reflétés dans les prochains états financiers.
MYND Life Sciences (MYNDF) hat die Genehmigung des Vorstands zur Ausgabe von 4.000.001 Stammaktien zu $0,71 pro Aktie bekannt gegeben, wodurch eine zuvor angekündigte Anleihe von $3,5 Millionen (CDN) vom 10. Januar 2025 beglichen wird. Der Gesamtwert der Aktienausgabe beläuft sich auf $2.840.000,71.
Das Unternehmen, das sich auf die Entwicklung von Arzneimitteltherapien und Diagnosen zur Behandlung und Überwachung von Depressionen konzentriert, betrachtet dies als einen bedeutenden Meilenstein. Laut CFO Lih Tam ermöglicht diese Entwicklung MYND, mit der Investmentgemeinschaft in Kontakt zu treten, während sie ihre Mission vorantreiben, die Major Depression zu bekämpfen. Die Einzelheiten der Anleiheabwicklung werden in den kommenden Finanzberichten berücksichtigt.
- Settlement of $3.5M debenture liability through share issuance, improving balance sheet structure
- Removal of debt obligation potentially strengthens financial position
- Dilution of existing shareholders through issuance of 4,000,001 new shares
Vancouver, British Columbia--(Newsfile Corp. - January 17, 2025) - MYND Life Sciences (CSE: MYND) (OTC Pink: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the development and commercialization of drug therapies and diagnostics to improve the monitoring and treatment of depression, today announced that the Board has approved the issuance of 4,000,001 common shares at
"We are pleased to announce that instructions to issue 4,000,001 shares for a total value of
The removal and details of the debenture will be reflected in MYND's upcoming financial statements.
About MYND Life Sciences (MYND)
MYND Life Sciences Inc. is a clinical-stage life sciences company focused on developing and commercializing drug therapies, along with a proprietary biomarker test, to diagnose and monitor the effectiveness of treatments for Major Depressive Disorder (MDD) and Treatment-resistant Depression (TRD). MYND's proprietary biomarker for depression has the potential to support personalized patient management strategies, leveraging the company's unique intellectual property and offering the possibility of near-term revenue opportunities. MYND is developing this test with the goal of being the first test to market of its kind, targeting depression, where there is a tremendous unmet need. For more information, you can visit www.myndsciences.com.
For more information please contact:
Lih Ming Tam, CFO
Email: ir@myndsciences.com
Phone: 604-813-9795
Web: www.myndsciences.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/237716
FAQ
How many shares did MYND Life Sciences (MYNDF) issue in January 2025?
What is the total value of MYNDF's January 2025 share issuance?
What was the purpose of MYNDF's January 2025 share issuance?
What is the price per share for MYNDF's January 2025 share issuance?
